Press Releases

SOTIO, a clinical stage immuno-oncology company, and Cytune Pharma, both owned by PPF Group, today announced new interim data from its Phase 1/1b study of SO-C101, an IL-15 superagonist, as a monotherapy and in combination with pembrolizumab in patients with advanced/metastatic solid tumors. The data are being presented in a late breaking poster at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting, held virtually this year on November 9-14, 2020. Two additional posters are al

Proteintech and HebeCell announced a collaboration to develop a proprietary nanobody based chimeric antigen receptor (nCAR) technology for development and the commercialization of induced pluripotent stem cell-derived natural killer cells (iPSC-nCAR-NK), a promising cellular immunotherapy for the treatment of cancer and other diseases. Proteintech's recent acquisition of nano-body manufacturer ChromoTek made the company a major player in the nano-body industry. ChromoTek's h

OrigiMed, a China-based leading precision medicine company and Takeda, a global biopharmaceutical company announced their strategic partnership to develop a genomic-based precision medicine platform during the 3rd China International Import Expo. With joint efforts, such a platform is believed to accelerate the R&D and commercialization of innovative medicines. Sean Shan, President of Takeda China and Senior Vice President of Takeda Pharmaceutical Company, Dr. Jie Chen, Director

The global contact services sector is benefiting from a switch towards COVID-19 manufacturing (vaccine and therapy) and clinical stage contracts, but mega-cap innovator drug approvals are reducing commercial demand according to the CPhI Annual Report contract services findings. Adam Bradbury, Analyst and Fiona Barry, Associate Editor at PharmSource GlobalData provided a holistic review of the trends, challenges and opportunities in the global contract manufacturing space.

SCHOTT AG, a global leader in pharmaceutical glass manufacturing, has inaugurated a new melting tank in its Gujarat-based facility with an approximate investment of EUR 25 Million. The new tank would help increasing the plant’s production capacity by 10,000 tonnes to reach an annual capacity of 40000 metric tonnes. SCHOTT AG has been a frontrunner in the global fight against Coronavirus, with commitment to provide its specialised pharma glass used for storing billions of COVID

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced the European Commission granted Orphan Drug designation to Forma’s FT-4202 for the treatment of sickle cell disease (SCD), based on a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA). FT-4202 was previously granted Fast Track, Rare Pediatric Disease and Orphan Drug designations from the U.S. Food

Renew Biopharma (“Renew”) announced that Algae-C Inc. (“Algae-C”) has licensed rights to employ Renew’s proprietary engineered enzymes for use toward biosynthesis of cannabinoids in microalgae. Renew’s portfolio of engineered enzymes are designed to support enhanced production of cannabinoids and cannabinoid derivatives. While Renew has employed these enzymes towards the company’s neurotherapeutic drug discovery program, these same enzymes c

AVITA Therapeutics, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today a preclinical research collaboration pairing AVITA Therapeutics’ proprietary Spray-On Skin™ Cells with Houston Methodist Research Institute’s expertise in reversing cellular aging. The project seeks to establish proof-of-concept for the development of a novel app

Pfizer Inc. and BioNTech SE announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study. After discussion with the FDA, the companies recently elected to drop the 32-case inter

MercachemSyncom, the leading mid-sized European drug-discovery contract research organization, announced that it has acquired Admescope Ltd. based in Oulu, Finland and Södertälje, Sweden. The acquisition will give MercachemSyncom significantly expanded capabilities for tailor-made in vitro and in vivo ADME-Tox studies for pre-clinical and early clinical R&D projects and seamless integration with the existing medicinal, synthetic and development chemistry capabilities of Mercache